Mustang Bio, INC Form 4 insider transactions

Mustang Bio's President, CEO, and Interim CFO, Manuel Litchman, reported a transaction involving the relinquishment of 19 common shares to cover tax liabilities.

Fortress Biotech, a 10% owner and director, acquired 278,385 shares of Mustang Bio common stock as a 2025 annual dividend, increasing its total beneficial ownership to 536,577 shares.

Mustang Bio Director Neil Herskowitz reported a private sale of 247 pre-split common shares at $0.962, with his remaining beneficial ownership adjusted for a recent one-for-fifty reverse stock split.

Mustang Bio Director Adam J. Chill reported the sale of 4 common shares at $0.9548 each, holding 375 shares post-transaction, adjusted for a recent reverse stock split.

Mustang Bio Director David Jin plans to acquire 247 shares of common stock in a private transaction on December 30, 2025, at $0.962 per share, adjusted for a prior reverse stock split.

Fortress Biotech, a 10% owner and director of Mustang Bio, acquired 59,334 shares of common stock as an equity fee, increasing its total beneficial ownership to 258,192 shares.

CEO Manuel Litchman relinquished 27 shares of Mustang Bio common stock to cover tax liabilities related to vesting restricted stock units.

Fortress Biotech, a 10% owner of Mustang Bio, acquired 67,806 shares of common stock as an equity fee and disposed of 198,858 shares on March 31, 2025.

Fortress Biotech, a 10% owner of Mustang Bio, acquired 575,191 shares of common stock as an equity fee following the closing of equity financings.

CEO Manuel Litchman reports relinquishing shares to cover tax liabilities and acquiring shares through the Employee Stock Purchase Plan.

CEO Manuel Litchman reports relinquishing shares to cover tax liabilities from vesting restricted stock units and acquiring shares through the Employee Stock Purchase Plan.